Found 6 matching trials
Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine PHASE2 This study is evaluating the safety and immunogenicity of GSK Biologicals' ...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age PHASE3 The primary phase of this study is evaluating the safety of Hib-MenCY-TT va...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 PHASE3 The purpose of the study is to characterize the immunogenicity \& safety of...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine PHASE3 This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT v...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age PHASE3 The purpose of this study is to evaluate the safety, reactogenicity and imm...
Show More Location
GSK Investigational Site
Learn More & Join Trial
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. PHASE3 The booster phase of the study will evaluate the safety of Hib-MenCY-TT vac...
Show More Location
GSK Investigational Site
Learn More & Join Trial